Key result
Moderate to severe vasoplegia following left ventricular assist device implantation was associated with a significantly higher risk of 1-year mortality (adjusted HR 2.12; 95% CI 1.08-4.18; P=0.03).
Why the study?
Does vasoplegia following left ventricular assist device implantation increase the risk of 1-year mortality?
Cohort (n=252)
Does vasoplegia following left ventricular assist device implantation increase the risk of 1-year mortality?
Hazard Ratio: 2.12 (95% CI 1.08–4.18)
p-value: p=0.03
Moderate to severe vasoplegia following LVAD implantation is a significant predictor of 1-year mortality and is associated with increased respiratory failure and major bleeding.
Moderate-severe vasoplegia after LVAD was associated with higher mortality; this Level 4 finding leaves open whether prevention alters outcomes.
Background Vasoplegia is associated with adverse outcomes following cardiac surgery; however, its impact following left ventricular assist device implantation is largely unexplored. Methods and Results In 252 consecutive patients receiving a left ventricular assist device, vasoplegia was defined as the occurrence of normal cardiac function and index but with the need for intravenous vasopressors within 48 hours following surgery for >24 hours to maintain a mean arterial pressure >70 mm Hg. We further categorized vasoplegia as none ; mild , requiring 1 vasopressor (vasopressin, norepinephrine, or high‐dose epinephrine [>5 μg/min]); or moderate to severe , requiring ≥2 vasopressors. Predictors of vasoplegia severity were determined using a cumulative logit (ordinal logistic regression) model, and 1‐year mortality was evaluated using competing‐risks survival analysis. In total, 67 (26.6%) patients developed mild vasoplegia and 57 (22.6%) developed moderate to severe vasoplegia. The multivariable model for vasoplegia severity utilized preoperative Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile, central venous pressure, systolic blood pressure, and intraoperative cardiopulmonary bypass time, which yielded an area under the curve of 0.76. Although no significant differences were noted in stroke or pump thrombosis rates ( P =0.87 and P =0.66, respectively), respiratory failure and major bleeding increased with vasoplegia severity ( P <0.01). Those with moderate to severe vasoplegia had a significantly higher risk of mortality than those without vasoplegia (adjusted hazard ratio: 2.12; 95% confidence interval, 1.08–4.18; P =0.03). Conclusions Vasoplegia is predictive of unfavorable outcomes, including mortality. Risk factors for future research include preoperative INTERMACS profile, central venous pressure, systolic blood pressure, and intraoperative cardiopulmonary bypass time.
No takes yet. Share an insight, caveat, or question.
Tecson et al. (2018) conducted a cohort in Left ventricular assist device implantation (n=252). Moderate to severe vasoplegia vs. No vasoplegia was evaluated on 1-year mortality (adjusted HR 2.12, 95% CI 1.08-4.18, p=0.03). Moderate to severe vasoplegia following left ventricular assist device implantation was associated with a significantly higher risk of 1-year mortality (adjusted HR 2.12; 95% CI 1.08-4.18; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: